ABRAXAS2
BRISC complex subunit Abraxas 2
Also known as: ABRO1, ABRX2_HUMAN, Em:AC068896.4, FAM175B, KIAA0157
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q15018
- Gene
- ABRAXAS2
- Ensembl
- ENSG00000165660
- Chromosome
- 10
- Canonical length
- 415 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Primary cilium transition zone,Basal body,Cytosol
OverviewNCBI Gene
Enables microtubule binding activity and polyubiquitin modification-dependent protein binding activity. Involved in nuclear chromosome segregation; protein K63-linked deubiquitination; and response to ischemia. Located in cytosol; microtubule cytoskeleton; and midbody. Part of BRISC complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
415 residues, UniProt reviewed canonical sequence.
>Q15018|ABRAXAS2
1 MAASISGYTF SAVCFHSANS NADHEGFLLG EVRQEETFSI SDSQISNTEF LQVIEIHNHQ
61 PCSKLFSFYD YASKVNEESL DRILKDRRKK VIGWYRFRRN TQQQMSYREQ VLHKQLTRIL
121 GVPDLVFLLF SFISTANNST HALEYVLFRP NRRYNQRISL AIPNLGNTSQ QEYKVSSVPN
181 TSQSYAKVIK EHGTDFFDKD GVMKDIRAIY QVYNALQEKV QAVCADVEKS ERVVESCQAE
241 VNKLRRQITQ RKNEKEQERR LQQAVLSRQM PSESLDPAFS PRMPSSGFAA EGRSTLGDAE
301 ASDPPPPYSD FHPNNQESTL SHSRMERSVF MPRPQAVGSS NYASTSAGLK YPGSGADLPP
361 PQRAAGDSGE DSDDSDYENL IDPTEPSNSE YSHSKDSRPM AHPDEDPRNT QTSQILocalizationUniProt · AlphaFold · HPA
Whether an antibody against ABRAXAS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.51
- Highest tissue expression
- 18 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 18 nTPM
- tongue: 15 nTPM
- liver: 13 nTPM
- tonsil: 13 nTPM
- parathyroid gland: 12 nTPM
- thymus: 12 nTPM
Single-cell type
- myonuclei: 51 nCPM
- oocytes: 37 nCPM
- thymic myoid cells: 37 nCPM
- esophageal apical cells: 36 nCPM
- retinal pigment epithelial cells: 34 nCPM
- neutrophil progenitors: 31 nCPM
Immune cell
- basophil: 23 nTPM
- intermediate monocyte: 15 nTPM
- myeloid DC: 13 nTPM
- non-classical monocyte: 12 nTPM
- naive B-cell: 12 nTPM
- T-reg: 11 nTPM
Brain region
- hypothalamus: 13 nTPM
- pons: 13 nTPM
- cerebral cortex: 13 nTPM
- midbrain: 13 nTPM
- basal ganglia: 12 nTPM
- cerebellum: 12 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.6
- gnomAD pLI
- 0.02
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- attachment of spindle microtubules to kinetochore
- cell division
- chromosome segregation
- mitotic cell cycle
- mitotic spindle assembly
- protein K63-linked deubiquitination
- response to ischemia
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- FAM175 family
- MPN domain
- BRCA1-A complex subunit Abraxas 1 MPN domain
- BRISC complex, Abraxas 2 subunit
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ABRAXAS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ABRAXAS2 as an antibody target. Whether an autoantibody or antibody against ABRAXAS2 could matter depends on whether native ABRAXAS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ABRAXAS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ABRAXAS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...